GleamWall
中文EN

GILD GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 882095 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.5%
TTM net income YoY-147.6%
TTM EPS YoY-148.5%
Revenue 3-yr CAGR4.2%
Net income 3-yr CAGR—

Margins

Gross margin79.9%
Operating margin-7.6%
Net margin-12.5%
FCF margin44.5%
EBITDA margin-6.3%

Returns

ROE-22.3%
ROA-7.0%
ROIC (approx.)-5.2%
Asset turnover0.56x

Leverage & solvency

Liabilities / assets74.8%
Debt / equity2.01x
Current ratio1.38x
Interest coverage-2.34x

Cash quality & payout

Operating cash flow / net income-3.75x
Accruals ratio-33.4%
Payout ratio—
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$8.30B$7.80B$6.96B$7.92B$7.77B$7.08B$6.67B$7.57B
Cost of revenue$1.57B$1.58B$1.45B$1.62B$1.57B$1.50B$1.54B$1.58B
Gross profit$6.73B$6.22B$5.51B$6.30B$6.20B$5.58B$5.13B$5.99B
R&D expense$1.61B$1.76B$1.37B$1.58B$1.35B$1.49B$1.38B$1.64B
SG&A expense$1.64B$1.92B$1.45B$1.79B$1.36B$1.36B$1.26B$1.91B
Operating income$3.46B-$10.39B$2.59B$1.98B$3.33B$2.47B$2.24B$2.45B
Interest expense$269.00M$247.00M$240.00M$255.00M$256.00M$254.00M$260.00M$249.00M
Pretax income$3.06B-$10.25B$2.58B$2.08B$3.64B$2.43B$1.65B$2.17B
Income tax$634.00M$242.00M$559.00M-$105.00M$589.00M$468.00M$334.00M$385.00M
Net income$2.43B-$10.50B$2.02B$2.18B$3.05B$1.96B$1.31B$1.78B
EBITDA$3.59B-$10.30B$2.68B$2.07B$3.42B$2.57B$2.33B$2.55B
EPS (basic)1.96-8.451.63—2.461.571.06—
EPS (diluted)1.94-8.451.61—2.431.561.04—
Dividends declared per share0.820.820.820.790.790.790.790.77
Weighted avg. shares (diluted)1.25B1.24B1.25B—1.25B1.25B1.26B—
Balance sheet
Cash & equivalents$6.44B$3.18B$7.63B$7.56B$7.33B$5.14B$7.93B$9.99B
Short-term investments$0$0$15.00M$68.00M$19.00M$69.00M—$0
Receivables$5.01B$5.05B$4.74B$4.91B$5.09B$4.78B$4.39B$4.42B
Inventory$1.90B$1.95B$1.91B$1.77B$1.78B$1.82B$1.76B$1.71B
Current assets$16.55B$13.95B$18.64B$18.34B$17.87B$14.72B$16.90B$19.17B
PP&E, net$5.95B$5.83B$5.64B$5.61B$5.50B$5.46B$5.42B$5.41B
Goodwill$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B$8.31B
Intangibles$13.42B$14.03B$16.38B$16.98B$17.97B$18.57B$19.36B$19.95B
Total assets$51.41B$49.36B$56.28B$59.02B$58.53B$55.72B$56.43B$58.99B
Current liabilities$12.00B$11.02B$9.48B$11.81B$12.30B$11.19B$12.34B$12.00B
Short-term debt$2.42B$2.41B$1.31B$2.81B$2.81B$2.81B$2.81B$1.81B
Long-term debt$23.82B$23.83B$20.86B$22.13B$22.14B$22.14B$22.15B$24.90B
Total debt$26.23B$26.25B$22.17B$24.94B$24.94B$24.95B$24.95B$26.71B
Total liabilities$38.45B$37.62B$32.85B$36.41B$37.08B$36.13B$37.36B$39.75B
Shareholders' equity$13.04B$11.83B$23.52B$22.70B$21.54B$19.67B$19.16B$19.33B
Net debt$19.79B$23.07B$14.55B$17.37B$17.61B$19.80B$17.03B$16.72B
Shares outstanding1.24B1.24B1.24B1.24B1.24B1.24B1.25B1.25B
Cash flow statement
Operating cash flow$5.04B$3.57B$2.54B$3.33B$4.11B$827.00M$1.76B$2.98B
Capital expenditure$237.00M$140.00M$117.00M$205.00M$147.00M$107.00M$104.00M$147.00M
Free cash flow$4.80B$3.43B$2.43B$3.12B$3.96B$720.00M$1.65B$2.83B
Investing cash flow-$244.00M-$10.35B$1.77B-$1.83B-$427.00M-$2.12B-$415.00M-$225.00M
Financing cash flow-$1.53B$2.34B-$4.24B-$1.26B-$1.49B-$1.57B-$3.43B$2.26B
Depreciation & amortization$132.00M$98.00M$93.00M$90.00M$90.00M$93.00M$97.00M$95.00M
Stock-based compensation$234.00M$231.00M$218.00M$230.00M$230.00M$225.00M$209.00M$222.00M
Dividends paid$1.04B$1.03B$1.04B$994.00M$1.00B$994.00M$1.01B$973.00M
Share buybacks$370.00M$355.00M$419.00M$230.00M$435.00M$527.00M$730.00M$350.00M

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.